betnovate 0.1% scalp application
waymade healthcare plc - betamethasone valerate - cutaneous liquid - 1mg/1gram
betnovate 0.1% scalp application
dowelhurst ltd - betamethasone valerate - cutaneous liquid - 1mg/1gram
betnovate 0.1% scalp application
de pharmaceuticals - betamethasone valerate - cutaneous liquid - 1mg/1gram
betnovate 0.1% scalp application
sigma pharmaceuticals plc - betamethasone valerate - cutaneous liquid - 1mg/1gram
betnovate 0.1% scalp application
lexon (uk) ltd - betamethasone valerate - cutaneous liquid - 1mg/1gram
betnovate scalp application
aspen pharmacare australia pty ltd - betamethasone valerate, quantity: 1.21 mg/g (equivalent: betamethasone, qty 1 mg/g) - lotion - excipient ingredients: carbomer 934p; isopropyl alcohol; sodium hydroxide; purified water - indications as at 23 april 2004 : eczema including : atopic, infantile, stasis and discoid eczemas. besnier's (flexural) prurigo. otitis externa. neurodermatoses including lichen simplex, lichen planus. seborrheic dermatitis, contact sensitivity reactions and allergies.
betnovate 1/5 cream
aspen pharmacare australia pty ltd - betamethasone valerate, quantity: 0.24 mg/g (equivalent: betamethasone, qty 0.2 mg/g) - cream - excipient ingredients: cetomacrogol 1000; cetostearyl alcohol; white soft paraffin; liquid paraffin; purified water; chlorocresol; monobasic sodium phosphate; phosphoric acid; sodium hydroxide - indications as at 23 april 2004 : eczema includiing: atopic, infantile, stasis and discoid eczemas. besnier's (flexural) prurigo. otitis externa. neurodermatoses including lichen simplex, lichen planus. seborrheic dermatitis, contact sensitivity reactions and allergies.
betnovate 0.1% scalp application
mawdsley-brooks & company ltd - betamethasone valerate - cutaneous liquid - 1mg/1gram
betnovate 0.1% scalp application
necessity supplies ltd - betamethasone valerate - cutaneous liquid - 1mg/1gram
initia renova extracorporeal shock wave therapy system
elogio asia pte. ltd. - physical medicine - renova is a low intensity extracorporeal shock wave therapy (lisw) device intended to deliver focused shockwaves onto a linear segment of a patient's penile shaft and crura; to improve erectile dysfunction (ed) symptoms; recommended patient characteristics are: good general health, erectile dysfunction (ed) of vascular origin, ed for at least 6 months but no longer than 7 years, international index of erectile function- erectile function domain score (iief-6) between 11 and 25 (mild to moderate ed).